Nalcaci M - Search Results

1

Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.

Kalayoglu-Besisik S, Ozturk GB, Caliskan Y, Nalcaci M, Gurses N, Cin N, Ozbek U, Sargin D. Kalayoglu-Besisik S, et al. Among authors: nalcaci m. Transfus Apher Sci. 2007 Feb;36(1):91-4. doi: 10.1016/j.transci.2006.05.018. Epub 2007 Jan 11. Transfus Apher Sci. 2007. PMID: 17222585

2

Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study.

Yenerel MN, Atamer T, Yavuz AS, Kucukkaya R, Besisik S, Aktan M, Keskin H, Nalcaci M, Sargin D, Pekcelen Y, Dincol G. Yenerel MN, et al. Among authors: nalcaci m. Ann Hematol. 2002 Sep;81(9):498-503. doi: 10.1007/s00277-002-0524-x. Epub 2002 Sep 6. Ann Hematol. 2002. PMID: 12373349

3

Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.

Palanduz S, Bayrak A, Sirma S, Vural B, Cefle K, Ucur A, Ozturk S, Yenerel MN, Besisik SK, Yavuz S, Diz-Kucukkaya R, Sargin D, Nalcaci M, Pekcelen Y, Ozbek U. Palanduz S, et al. Among authors: nalcaci m. Genet Test Mol Biomarkers. 2009 Oct;13(5):599-602. doi: 10.1089/gtmb.2009.0055. Genet Test Mol Biomarkers. 2009. PMID: 19814615

4

Investigation of Arg399Gln and Arg194Trp polymorphisms of the XRCC1 (x-ray cross-complementing group 1) gene and its correlation to sister chromatid exchange frequency in patients with chronic lymphocytic leukemia.

Duman N, Aktan M, Ozturk S, Palanduz S, Cakiris A, Ustek D, Ozbek U, Nalcaci M, Cefle K. Duman N, et al. Among authors: nalcaci m. Genet Test Mol Biomarkers. 2012 Apr;16(4):287-91. doi: 10.1089/gtmb.2011.0152. Epub 2011 Nov 22. Genet Test Mol Biomarkers. 2012. PMID: 22106831

5

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.

Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D. Yonal-Hindilerden I, et al. Among authors: nalcaci m. J Clin Med Res. 2015 Mar;7(3):161-70. doi: 10.14740/jocmr2047w. Epub 2014 Dec 29. J Clin Med Res. 2015. PMID: 25584101 Free PMC article.

6

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.

Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D. Yonal-Hindilerden I, et al. Among authors: nalcaci m. J Blood Med. 2015 Jun 1;6:157-75. doi: 10.2147/JBM.S78826. eCollection 2015. J Blood Med. 2015. PMID: 26082670 Free PMC article.

7

The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.

Yonal-Hindilerden I, Daglar-Aday A, Hindilerden F, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, Sargin D. Yonal-Hindilerden I, et al. Among authors: nalcaci m. J Clin Med Res. 2016 Jan;8(1):29-39. doi: 10.14740/jocmr2405w. Epub 2015 Dec 3. J Clin Med Res. 2016. PMID: 26668680 Free PMC article.

8

The frequency of C609T polymorphism in the NQO1 gene and its relation to cytogenetic abnormalities in patients with myelodysplastic syndrome.

Bagatir G, Sirma S, Palanduz S, Ozturk S, Cefle K, Ozbek U, Yenerel M, Nalcaci M. Bagatir G, et al. Among authors: nalcaci m. Cell Mol Biol (Noisy-le-grand). 2016 Jun 30;62(7):61-5. Cell Mol Biol (Noisy-le-grand). 2016. PMID: 27453274

9

A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.

Demir S, Gelincik A, Coskun R, Ozkan G, Demir N, Paksoy N, Beyaz S, Colakoglu B, Kalayoglu-Besisik S, Nalcacı M, Buyukozturk S. Demir S, et al. Among authors: nalcaci m. Ann Allergy Asthma Immunol. 2019 Oct;123(4):394-397. doi: 10.1016/j.anai.2019.07.031. Epub 2019 Aug 7. Ann Allergy Asthma Immunol. 2019. PMID: 31400463

10

Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.

Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN, Elverdi T, Kaynar L, Ayyildiz O, Yonal Hindilerden I, Goksoy HS, Izmir Guner S, Gunes AK, Sonmez M, Kurt Yuksel M, Civriz Bozdag S, Ozkurt ZN, Toptas T, Dogu MH, Salim O, Saydam G, Yavasoglu I, Ayli M, Ozet G, Albayrak M, Birtas Atesoglu E, Toprak SK, Yildirim R, Mehtap O, Kalayoglu Besisik S, Nalcaci M, Altuntas F, Ferhanoglu B. Akay OM, et al. Among authors: nalcaci m. Hematol Oncol. 2021 Oct;39(4):498-505. doi: 10.1002/hon.2897. Epub 2021 Jun 25. Hematol Oncol. 2021. PMID: 34171130

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters